1.
Bouchillon SK, Johnson BM, Hoban DJ, Johnson JL, Dowzicky MJ, Wu DH, et al. Determining incidence of extended spectrum beta-lactamase producing Enterobacteriaceae, vancomycin-resistant Enterococcus faecium and methicillin-resistant Staphylococcus aureus in 38 centres from 17 countries: the PEARLS study 2001–2002. Int J Antimicrob Agents. 2004 Aug;24(2):119–124. [PubMed: 15288309]
2.
Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997–2002) Diagn Microbiol Infect Dis. 2004 Sep;50(1):59–69. [PubMed: 15380279]
3.
Streit JM, Jones RN, Sader HS, Fritsche TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America: 2001) Int J Antimicrob Agents. 2004 Aug;24(2):111–118. [PubMed: 15288308]
4.
National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control. 1999 Dec;27(6):520–532. [PubMed: 10586157]
5.
Pearman JW. 2004 Lowbury Lecture: the Western Australian experience with vancomycin-resistant enterococci - from disaster to ongoing control. J Hosp Infect. 2006;63(1):14–26. [PubMed: 16563562]
6.
Yeh KM, Siu LK, Chang JC, Chang FY. Vancomycin-resistant Enterococcus (VRE) carriage and infection in intensive care units. Microb Drug Resist. 2004;10(2):177–183. [PubMed: 15256034]
7.
Risks of extended-spectrum beta-lactamases. Drug Ther Bull. 2008;46(3):21–24. [PubMed: 18337463]
8.
Carbonne A, Albertini MT, Astagneau P, Benoit C, Berardi L, Berrouane Y, et al. Surveillance of methicillin-resistant Staphylococcus aureus (MRSA) and Enterobacteriaceae producing extended-spectrum beta-lactamase (ESBLE) in Northern France: a five-year multicentre incidence study. J Hosp Infect. 2002;52(2):107–113. [PubMed: 12398076]
9.
Zirakzadeh A, Patel R. Vancomycin-resistant enterococci: colonization, infection, detection, and treatment. Mayo Clin Proc. 2006 Apr;81(4):529–536. [PubMed: 16610573]
10.
Bush K. New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis. 2001 Apr 1;32(7):1085–1089. [PubMed: 11264037]
11.
Ofner-Agostini M, Johnston BL, Simor AE, Embil J, Matlow A, Mulvey M, et al. Vancomycin-resistant enterococci in Canada: results from the Canadian nosocomial infection surveillance program, 1999–2005. Infect Control Hosp Epidemiol. 2008 Mar;29(3):271–274. [PubMed: 18241031]
12.
Zhanel GG, DeCorby M, Adam H, Mulvey MR, McCracken M, Lagace-Wiens P, et al. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008) Antimicrob Agents Chemother [Internet] 2010 Nov;54(11):4684–4693. [cited 2012 Mar 7]; Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC2976152. [PMC free article: PMC2976152] [PubMed: 20805395]
13.
Johnston BL, Bryce E. Hospital infection control strategies for vancomycin-resistant Enterococcus, methicillin-resistant Staphylococcus aureus and Clostridium difficile. CMAJ [Internet] 2009 Mar 17;180(6):627–631. [cited 2012 Mar 2]; Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC2653571. [PMC free article: PMC2653571] [PubMed: 19289807]
14.
Office of the Auditor General of Ontario. Toronto: The Office; Prevention and control of hospital-acquired infections: special report [Internet] 2008 Sep [cited 2012 Mar 2]; Available from: http://www​.auditor.on​.ca/en/reports_en/hai_en.pdf.
15.
Provincial Infection Control Network of British Columbia (PICNet) Vancouver: PICNet; Antibiotic resistant organisms prevention and control guidelines [Internet] 2008 Nov [cited 2012 Mar 2]; Available from: http://www​.bccdc.ca/NR​/rdonlyres/F4154D6F-DB88-4D2C-9973-8421F3B934AF​/0/InfectionControl​_GF_ARO_Guidelines_November2008​.pdf.
16.
Provincial Infectious Diseases Advisory Committee (PIDAC) Annex A - screening, testing and surveillance for antibiotic-resistant organisms (AROs) in all health care settings. Toronto: Ontario Agency for Health Protection and Promotion; Annexed to: routine practices and additional precautions in all health care settings. [Internet] (4th revision). 2012 Feb [cited 2012 Jul 17]; Available from: http://www​.oahpp.ca/resources​/documents/pidac​/Annex%20A%20-%20PHO​%20template%20-​%20REVISION%20-%202012Apr25.pdf.
17.
Siegel JD, Rhinehart E, Jackson M, Chiarello L. Healthcare Infection Control Practices Advisory Committee. Atlanta: Centers for Disease Control and Prevention; Management of multidrug-resistant organisms in healthcare settings [Internet] 2006 [cited 2012 Mar 2]; Available from: http://www​.cdc.gov/hicpac​/pdf/MDRO/MDROGuideline2006.pdf. [PubMed: 18068814]
18.
Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol. 2003 May;24(5):362–386. [PubMed: 12785411]
19.
Vandijck DM, Depuydt PO, Blot SI. Antibiotic resistance in the ICU: clinical and cost aspects. Neth J Crit Care. 2008;12(1):20–25.
20.
Rabinowitz RP, Kufera JA, Makley MJ. A hidden reservoir of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in patients newly admitted to an acute rehabilitation hospital. PM R. 2012 Jan;4(1):18–22. [PubMed: 22269450]
21.
Reddy P, Malczynski M, Obias A, Reiner S, Jin N, Huang J, et al. Screening for extended-spectrum beta-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis [Internet] 2007 Oct 1;45(7):846–852. [cited 2012 Apr 4]; Available from: http://cid​.oxfordjournals​.org/content/45/7/846.full.pdf+html. [PubMed: 17806048]
22.
Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol. 2003 Sep;24(9):690–698. [PubMed: 14510253]
23.
DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis. 2005 Aug 1;41(3):327–333. [PubMed: 16007529]
24.
Tacconelli E, Cauda R, Cataldo MAA, Carmeli Y, De Angelis G. Control interventions for preventing spread of vancomycin-resistant enterococci (VRE) in hospitals. Cochrane Database Syst Rev. 2008;(4):CD007420.
25.
Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs. 2002;62(3):425–441. [PubMed: 11827558]
26.
Tacconelli E. Screening and isolation for infection control. J Hosp Infect. 2009 Dec;73(4):371–377. [PubMed: 19699554]
27.
VRE surveillance &isolation changes in practice at the Ottawa Hospital: important notice. Ottawa: The Ottawa Hospital; Jun 12, 2012.
28.
Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis [Internet] 2003 Jun 1;36(11):1433–1437. [cited 2012 Apr 13]; Available from: http://cid​.oxfordjournals​.org/content/36/11/1433​.full.pdf+html. [PubMed: 12766839]
29.
Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health [Internet] 1998 Jun;52(6):377–384. [cited 2012 Aug 8]; Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles​/PMC1756728/pdf/v052p00377.pdf. [PMC free article: PMC1756728] [PubMed: 9764259]
30.
Price CS, Paule S, Noskin GA, Peterson LR. Active surveillance reduces the incidence of vancomycin-resistant enterococcal bacteremia. Clin Infect Dis. 2003;37(7):921–928. [PubMed: 13130403]
31.
Wang JT, Chen YC, Chang SC, Chen ML, Pan HJ, Chang YY, et al. Control of vancomycin-resistant enterococci in a hospital: a five-year experience in a Taiwanese teaching hospital. J Hosp Infect. 2004;58(2):97–103. [PubMed: 15474179]
32.
Yoonchang SW, Peck KR, Kim OS, Lee JH, Lee NY, Oh WS, et al. Efficacy of infection control strategies to reduce transmission of vancomycin-resistant enterococci in a tertiary care hospital in Korea: a 4-year follow-up study. Infect Control Hosp Epidemiol. 2007 Apr;28(4):493–495. [PubMed: 17385160]
33.
Catalano G, Houston SH, Catalano MC, Butera AS, Jennings SM, Hakala SM, et al. Anxiety and depression in hospitalized patients in resistant organism isolation. South Med J. 2003 Feb;96(2):141–145. [PubMed: 12630637]
34.
Day HR, Perencevich EN, Harris AD, Himelhoch SS, Brown CH, Gruber-Baldini AL, et al. Do contact precautions cause depression? A two-year study at a tertiary care medical centre. J Hosp Infect. 2011;79(2):103–107. [PMC free article: PMC3331706] [PubMed: 21664000]
35.
Laurent C, Rodriguez-Villalobos H, Rost F, Strale H, Vincent JL, Deplano A, et al. Intensive care unit outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae controlled by cohorting patients and reinforcing infection control measures. Infect Control Hosp Epidemiol. 2008 Jun;29(6):517–524. [PubMed: 18510461]
36.
Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med [Internet] 2009 Jul 21;6(7):e1000097. [cited 2012 Apr 2]; Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles/PMC2707599. [PMC free article: PMC2707599] [PubMed: 19621072]
37.
Carmeli Y, Eliopoulos G, Mozaffari E, Samore M. Health and economic outcomes of vancomycin-resistant enterococci. Arch Intern Med. 2002 Oct 28;162(19):2223–2228. [PubMed: 12390066]
38.
Stone PW, Gupta A, Loughrey M, Della-Latta P, Cimiotti J, Larson E, et al. Attributable costs and length of stay of an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae outbreak in a neonatal intensive care unit. Infect Control Hosp Epidemiol. 2003 Aug;24(8):601–606. [PubMed: 12940582]
39.
Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol. 2006 Nov;27(11):1226–1232. [PubMed: 17080381]
40.
Conterno LO, Shymanski J, Ramotar K, Toye B, Zvonar R, Roth V. Impact and cost of infection control measures to reduce nosocomial transmission of extended-spectrum beta-lactamase-producing organisms in a non-outbreak setting. J Hosp Infect. 2007 Apr;65(4):354–360. [PubMed: 17289215]
41.
Stelfox HT, Bates DW, Redelmeier DA. Safety of patients isolated for infection control. JAMA. 2003 Oct 8;290(14):1899–1905. [PubMed: 14532319]
42.
Weber DJ, Sickbert-Bennett EE, Brown V, Rutala WA. Comparison of hospitalwide surveillance and targeted intensive care unit surveillance of healthcare-associated infections. Infect Control Hosp Epidemiol. 2007 Dec;28(12):1361–1366. [PubMed: 17994516]
43.
Hamel M, Zoutman D, O'Callaghan C. Exposure to hospital roommates as a risk factor for health care-associated infection. Am J Infect Control. 2010 Apr;38(3):173–181. [PubMed: 20022405]
44.
Johnson D, Lineweaver L, Maze LM. Patients' bath basins as potential sources of infection: a multicenter sampling study. Am J Crit Care. 2009 Jan;18(1):31–38. [PubMed: 19116402]
45.
Tekerekoglu MS, Duman Y, Serindag A, Cuglan SS, Kaysadu H, Tunc E, et al. Do mobile phones of patients, companions and visitors carry multidrug-resistant hospital pathogens? Am J Infect Control. 2011 Jun;39(5):379–381. [PubMed: 21624635]
46.
Treakle AM, Thom KA, Furuno JP, Strauss SM, Harris AD, Perencevich EN. Bacterial contamination of health care workers' white coats. Am J Infect Control [Internet] 2009 Mar;37(2):101–105. [cited 2012 Apr 3]; Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles​/PMC2892863/pdf/nihms185144.pdf. [PMC free article: PMC2892863] [PubMed: 18834751]
47.
Wilson JA, Loveday HP, Hoffman PN, Pratt RJ. Uniform: an evidence review of the microbiological significance of uniforms and uniform policy in the prevention and control of healthcare-associated infections. Report to the Department of Health (England) J Hosp Infect. 2007;66(4):301–307. [PubMed: 17602793]
48.
Scheithauer S, Oberrohrmann A, Haefner H, Kopp R, Schurholz T, Schwanz T, et al. Compliance with hand hygiene in patients with meticillin-resistant Staphylococcus aureus and extended-spectrum beta-lactamase-producing enterobacteria. J Hosp Infect. 2010 Dec;76(4):320–323. [PubMed: 20970881]
49.
Venkatesh AK, Lankford MG, Rooney DM, Blachford T, Watts CM, Noskin GA. Use of electronic alerts to enhance hand hygiene compliance and decrease transmission of vancomycin-resistant Enterococcus in a hematology unit. Am J Infect Control. 2008 Apr;36(3):199–205. [PubMed: 18371516]
50.
Kho AN, Dexter PR, Warvel JS, Belsito AW, Commiskey M, Wilson SJ, et al. An effective computerized reminder for contact isolation of patients colonized or infected with resistant organisms. Int J Med Inform [Internet] 2008 Mar;77(3):194–198. [cited 2012 Apr 2]; Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles​/PMC2974622/pdf/nihms244632.pdf. [PMC free article: PMC2974622] [PubMed: 17398145]
51.
Aboelela SW, Saiman L, Stone P, Lowy FD, Quiros D, Larson E. Effectiveness of barrier precautions and surveillance cultures to control transmission of multidrug-resistant organisms: a systematic review of the literature. Am J Infect Control. 2006 Oct;34(8):484–494. [PubMed: 17015153]
52.
Goddard S, Muller MP. The efficacy of infection control interventions in reducing the incidence of extended-spectrum beta-lactamase-producing Enterobacteriaceae in the nonoutbreak setting: a systematic review. Am J Infect Control. 2011 Sep;39(7):599–601. [PubMed: 21621295]
53.
Washer LL, Chenoweth CE. Infection control strategies for methicillin-resistant staphylococcus aureus and vancomycin-resistant Enterococcus: what is the evidence? J Clin Outcomes Manage. 2006;13(6):333–341.
54.
Zoutman DE, Ford BD. A comparison of infection control program resources, activities, and antibiotic resistant organism rates in Canadian acute care hospitals in 1999 and 2005: pre- and post-severe acute respiratory syndrome. Am J Infect Control. 2008 Dec;36(10):711–717. [PubMed: 18834747]
55.
Ofner-Agostini M, Varia M, Johnston L, Green K, Simor A, Amihod B, et al. Infection control and antimicrobial restriction practices for antimicrobial-resistant organisms in Canadian tertiary care hospitals. Am J Infect Control. 2007 Nov;35(9):563–568. [PubMed: 17980232]
56.
Zoutman DE, Ford BD. The relationship between hospital infection surveillance and control activities and antibiotic-resistant pathogen rates. Am J Infect Control. 2005 Feb;33(1):1–5. [PubMed: 15685127]
57.
Peirano G, Laupland KB, Gregson DB, Pitout JD. Colonization of returning travelers with CTX-M-producing Escherichia coli. J Travel Med. 2011 Sep;18(5):299–303. [PubMed: 21896092]
58.
Tangden T, Cars O, Melhus A, Lowdin E. Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers. Antimicrob Agents Chemother. 2010 Sep;54(9):3564–3568. [PMC free article: PMC2934993] [PubMed: 20547788]
59.
Kennedy K, Collignon P. Colonisation with Escherichia coli resistant to "critically important" antibiotics: a high risk for international travellers. Eur J Clin Microbiol Infect Dis. 2010;29(12):1501–1506. [PubMed: 20835879]